Literature DB >> 2119871

Ionic versus nonionic contrast media: a burden or a bargain?

A Gafni1, C J Zylak.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2119871      PMCID： PMC1452286     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  10 in total

1.  The quality of QALYs (quality-adjusted-life-years): do QALYs measure what they at least intend to measure?

Authors:  A Gafni
Journal:  Health Policy       Date:  1989-10       Impact factor: 2.980

Review 2.  The use of QALYs in health care decision making.

Authors:  G Loomes; L McKenzie
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

Review 3.  Measurement of health state utilities for economic appraisal.

Authors:  G W Torrance
Journal:  J Health Econ       Date:  1986-03       Impact factor: 3.883

4.  Evaluation of public investment in health care. Is the risk irrelevant?

Authors:  U Ben-Zion; A Gafni
Journal:  J Health Econ       Date:  1983-08       Impact factor: 3.883

5.  Quality-adjusted life years, utility theory, and healthy-years equivalents.

Authors:  A Mehrez; A Gafni
Journal:  Med Decis Making       Date:  1989 Apr-Jun       Impact factor: 2.583

6.  Nonionic contrast media: economic analysis and health policy development.

Authors:  V Goel; R B Deber; A S Detsky
Journal:  CMAJ       Date:  1989-02-15       Impact factor: 8.262

7.  [Iohexol in excretory urography. Results of drug monitoring].

Authors:  K M Schrott; B Behrends; W Clauss; J Kaufmann; J Lehnert
Journal:  Fortschr Med       Date:  1986-02-20

8.  Adverse reactions to contrast media: a report from the Committee on Safety of Contrast Media of the International Society of Radiology.

Authors:  W H Shehadi; G Toniolo
Journal:  Radiology       Date:  1980-11       Impact factor: 11.105

Review 9.  Systemic reactions to intravascular contrast media. A guide for the anesthesiologist.

Authors:  M Goldberg
Journal:  Anesthesiology       Date:  1984-01       Impact factor: 7.892

10.  Fallacy of the five-year survival in lung cancer.

Authors:  B J McNeil; R Weichselbaum; S G Pauker
Journal:  N Engl J Med       Date:  1978-12-21       Impact factor: 91.245
  10 in total
  4 in total

1.  Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).

Authors:  A Mehrez; A Gafni
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

2.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations.

Authors:  A Laupacis; D Feeny; A S Detsky; P X Tugwell
Journal:  CMAJ       Date:  1992-02-15       Impact factor: 8.262

Review 3.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

4.  Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem.

Authors:  A Gafni; S Birch
Journal:  CMAJ       Date:  1993-03-15       Impact factor: 8.262
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.